Breaking News Instant updates and real-time market news.

XEBEF

Xebec Adsorption

$0.00 /

+ (+0.00%)

12:39
03/16/21
03/16
12:39
03/16/21
12:39

Xebec Adsorption price target lowered to C$7.50 from C$13 at Desjardins

Desjardins analyst Frederic Tremblay lowered the firm's price target on Xebec Adsorption to C$7.50 from C$13 and keeps a Buy rating on the shares.

OTHER BREAKING NEWS FROM THE FLY

General news
Asian Market Update: » 03:05
01/17/22
01/17
03:05
01/17/22
03:05
$ECON

Economic Data

/

+

Asian Market Update:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Conference/Events
Osmotica Pharmaceuticals to host business news update conference call » 23:28
01/16/22
01/16
23:28
01/16/22
23:28
OSMT

Osmotica Pharmaceuticals

$1.10 /

-0.03 (-2.65%)

CEO Markison and COO…

CEO Markison and COO Schaub discuss recent UPNEEQ trends, pending expansion into the medical Aesthetics market and other general business updates on a conference call to be held on January 19 at 8:30 am. Webcast Link

ShowHide Related Items >><<
OSMT Osmotica Pharmaceuticals
$1.10 /

-0.03 (-2.65%)

OSMT Osmotica Pharmaceuticals
$1.10 /

-0.03 (-2.65%)

12/23/21 H.C. Wainwright
Osmotica Pharmaceuticals initiated with a Buy at H.C. Wainwright
11/09/21 Jefferies
Osmotica Pharmaceuticals resumed with a Buy at Jefferies
10/11/21 Truist
Osmotica Pharmaceuticals price target lowered to $5 from $7 at Truist
09/24/21 Cantor Fitzgerald
Osmotica Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
OSMT Osmotica Pharmaceuticals
$1.10 /

-0.03 (-2.65%)

  • 07
    Oct
OSMT Osmotica Pharmaceuticals
$1.10 /

-0.03 (-2.65%)

OSMT Osmotica Pharmaceuticals
$1.10 /

-0.03 (-2.65%)

Conference/Events
KemPharm to host business news update conference call » 23:22
01/16/22
01/16
23:22
01/16/22
23:22
KMPH

KemPharm

$8.17 /

+0.015 (+0.18%)

Conference call to…

Conference call to discuss the Company's strategy for advancing and expanding its development pipeline will be held on January 19 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
KMPH KemPharm
$8.17 /

+0.015 (+0.18%)

KMPH KemPharm
$8.17 /

+0.015 (+0.18%)

05/26/21 Roth Capital
Orange Book lists 6 KemPharm SDX patents, confirms as an NCE, says Roth Capital
03/04/21 H.C. Wainwright
KemPharm downgraded to Neutral from Buy at H.C. Wainwright
01/25/21 Roth Capital
KemPharm initiated with a Buy at Roth Capital
KMPH KemPharm
$8.17 /

+0.015 (+0.18%)

Conference/Events
FTC Solar to host business news update conference call » 22:57
01/16/22
01/16
22:57
01/16/22
22:57
FTCI

FTC Solar

$5.13 /

-0.945 (-15.56%)

CEO Hunkler holds a…

CEO Hunkler holds a business news update conference call on January 18 at 8:30 am. Webcast Link

ShowHide Related Items >><<
FTCI FTC Solar
$5.13 /

-0.945 (-15.56%)

FTCI FTC Solar
$5.13 /

-0.945 (-15.56%)

01/14/22 BofA
FTC Solar downgraded to Underperform from Neutral at BofA
01/07/22 Piper Sandler
FTC Solar price target lowered to $14 from $17 at Piper Sandler
11/16/21 Roth Capital
Roth says court restoring solar 'bifi' exemption a 'major surprise'
11/15/21 Roth Capital
Roth Capital not expecting A-SMACC to reveal petitioner to keep anti-circ case alive
FTCI FTC Solar
$5.13 /

-0.945 (-15.56%)

  • 28
    Apr
FTCI FTC Solar
$5.13 /

-0.945 (-15.56%)

FTCI FTC Solar
$5.13 /

-0.945 (-15.56%)

FTCI FTC Solar
$5.13 /

-0.945 (-15.56%)

Upgrade
Brookfield Renewable Partners upgraded to Outperform at BMO Capital » 19:51
01/16/22
01/16
19:51
01/16/22
19:51
BEP

Brookfield Renewable Partners

$32.72 /

-0.895 (-2.66%)

BMO Capital analyst Ben…

BMO Capital analyst Ben Pham upgraded Brookfield Renewable Partners to Outperform from Market Perform with a price target of $38, down from $40. The company offers "industry-leading" 10%-plus growth and has "strong" investment grade-rated balance sheet that can fund growth without requiring external equity, Pham tells investors in a research note. As one of the largest publicly traded renewable power companies with a global footprint across all key technologies, Brookfield Renewable Partners is the "go-to" for renewable power investment, adds the analyst.

ShowHide Related Items >><<
BEP Brookfield Renewable Partners
$32.72 /

-0.895 (-2.66%)

BEP Brookfield Renewable Partners
$32.72 /

-0.895 (-2.66%)

01/11/22 CIBC
Brookfield Renewable Partners upgraded with $40 target at CIBC
01/10/22 CIBC
Brookfield Renewable Partners upgraded to Outperformer from Neutral at CIBC
01/07/22 Scotiabank
Brookfield Renewable Partners upgraded at Scotiabank after December weakness
01/07/22 Scotiabank
Brookfield Renewable Partners upgraded to Outperform from Sector Perform at Scotiabank
BEP Brookfield Renewable Partners
$32.72 /

-0.895 (-2.66%)

BEP Brookfield Renewable Partners
$32.72 /

-0.895 (-2.66%)

BEP Brookfield Renewable Partners
$32.72 /

-0.895 (-2.66%)

Upgrade
Northland Power upgraded to Outperform from Market Perform at BMO Capital » 19:49
01/16/22
01/16
19:49
01/16/22
19:49
NPIFF

Northland Power

$28.11 /

-0.4 (-1.40%)

BMO Capital analyst Ben…

BMO Capital analyst Ben Pham upgraded Northland Power to Outperform from Market Perform with a price target of C$41, down from C$44. The analyst has a positive EBITDA outlook for 2022 and sees "free upside optionality" from the company's off-shore wind project roster. He also views the stock's relative valuation as attractive relative valuation.

ShowHide Related Items >><<
NPIFF Northland Power
$28.11 /

-0.4 (-1.40%)

NPIFF Northland Power
$28.11 /

-0.4 (-1.40%)

01/11/22 CIBC
Northland Power price target lowered to C$43 from C$45 at CIBC
12/02/21 National Bank
Northland Power price target lowered to C$44 from C$48 at National Bank
11/11/21 Scotiabank
Northland Power price target lowered to C$47.75 from C$48.25 at Scotiabank
10/21/21 CIBC
Northland Power price target lowered to C$45 from C$46 at CIBC
Conference/Events
Cardiff Oncology to hold a conference call » 16:57
01/16/22
01/16
16:57
01/16/22
16:57
CRDF

Cardiff Oncology

$6.85 /

+0.04 (+0.59%)

Management discusses…

Management discusses updated data from the Company's lead clinical program in KRAS-mutated metastatic colorectal cancer on a conference call to be held on January 18 at 5 pm. Webcast Link

ShowHide Related Items >><<
CRDF Cardiff Oncology
$6.85 /

+0.04 (+0.59%)

CRDF Cardiff Oncology
$6.85 /

+0.04 (+0.59%)

12/07/21 Baird
Cardiff Oncology initiated with an Outperform at Baird
11/18/21 Piper Sandler
Cardiff investment by Pfizer 'some nice validation,' says Piper Sandler
09/09/21 Maxim
Cardiff Oncology price target raised to $25 from $20 at Maxim
09/09/21 Piper Sandler
Cardiff colorectal cancer data 'very consistent,' says Piper Sandler
CRDF Cardiff Oncology
$6.85 /

+0.04 (+0.59%)

CRDF Cardiff Oncology
$6.85 /

+0.04 (+0.59%)

Conference/Events
Corsair Gaming to host virtual investor day » 16:52
01/16/22
01/16
16:52
01/16/22
16:52
CRSR

Corsair Gaming

$20.71 /

+0.1 (+0.49%)

Virtual Investor Day to…

Virtual Investor Day to be held on January 20 at 10 am . Webcast Link

ShowHide Related Items >><<
CRSR Corsair Gaming
$20.71 /

+0.1 (+0.49%)

CRSR Corsair Gaming
$20.71 /

+0.1 (+0.49%)

11/03/21 Barclays
Corsair Gaming price target lowered to $34 from $42 at Barclays
10/26/21 DA Davidson
Corsair Gaming price target lowered to $40 from $47 at DA Davidson
10/18/21 Cowen
Corsair Gaming price target lowered to $32 from $37 at Cowen
10/15/21 Baird
Corsair Gaming downgraded to Neutral at Baird on supply chain constraints
CRSR Corsair Gaming
$20.71 /

+0.1 (+0.49%)

  • 22
    Jan
CRSR Corsair Gaming
$20.71 /

+0.1 (+0.49%)

CRSR Corsair Gaming
$20.71 /

+0.1 (+0.49%)

Conference/Events
Conn's to host virtual investor day » 16:46
01/16/22
01/16
16:46
01/16/22
16:46
CONN

Conn's

$22.87 /

-1.725 (-7.02%)

Virtual Investor Day to…

Virtual Investor Day to be held on January 20 at 9 am. Webcast Link

ShowHide Related Items >><<
CONN Conn's
$22.87 /

-1.725 (-7.02%)

CONN Conn's
$22.87 /

-1.725 (-7.02%)

Downgrade
SJM Holdings downgraded to Buy from Conviction Buy at Goldman Sachs » 16:03
01/16/22
01/16
16:03
01/16/22
16:03
SJMHY

SJM Holdings

$2.77 /

+0.205 (+7.99%)

, SCHYY

Sands China

$27.25 /

+5.46 (+25.06%)

Goldman Sachs analyst…

Goldman Sachs analyst Simon Cheung removed SJM Holdings (SJMHY) from the firm's Conviction List, while keeping a Buy rating on the name with a price target of HK$7.90, down from HK$9.60. Cheung has switched his Macau gaming sector top preference for local stocks from SJM to Sands China (SCHYY), which is replacing SJM on the Conviction List, as he now sees more upside in the near-term for Sands China from closing its valuation discount versus peers following the release of details of the region's proposed gaming law revision. SJM does not own the 14 satellite casinos in the Macau peninsula it has been operating under revenue sharing agreements with property owners and has been given a three-year transitional period to resolve and/or terminate its satellite arrangements, Cheung noted.

ShowHide Related Items >><<
SJMHY SJM Holdings
$2.77 /

+0.205 (+7.99%)

SJMHY SJM Holdings
$2.77 /

+0.205 (+7.99%)

11/26/21 Credit Suisse
Credit Suisse upgrades Macau stocks with 'light at the end of the tunnel'
11/24/21 Credit Suisse
SJM Holdings upgraded to Outperform from Neutral at Credit Suisse
09/15/21 JPMorgan
SJM Holdings downgraded to Neutral from Overweight at JPMorgan
02/08/21 JPMorgan
SJM Holdings upgraded to Overweight from Neutral at JPMorgan
SCHYY Sands China
$27.25 /

+5.46 (+25.06%)

01/16/22 Goldman Sachs
Sands China upgraded to Conviction Buy from Buy at Goldman Sachs
11/24/21 Credit Suisse
Sands China upgraded to Outperform from Neutral at Credit Suisse
11/19/21 JPMorgan
Sands China upgraded to Neutral from Underweight at JPMorgan
SJMHY SJM Holdings
$2.77 /

+0.205 (+7.99%)

Periodicals
Airlines cancel over 2,700 U.S. flights as winter storm hits East Coast, Reuters » 15:46
01/16/22
01/16
15:46
01/16/22
15:46
ALK

Alaska Air

$55.79 /

-0.715 (-1.27%)

, LUV

Southwest

$45.84 /

+0.045 (+0.10%)

, DAL

Delta Air Lines

$40.31 /

-1.15 (-2.77%)

, JBLU

JetBlue

$14.85 /

-0.28 (-1.85%)

, UAL

United Airlines

$46.74 /

-1.39 (-2.89%)

, SAVE

Spirit Airlines

$23.30 /

-0.48 (-2.02%)

, AAL

American Airlines

$18.50 /

-0.84 (-4.34%)

Airlines canceled over…

Airlines canceled over 2,700 U.S. flights on Sunday as a winter storm combining high winds and ice was poised to hit the U.S. East Coast over the holiday weekend, Reuters' Kanishka Singh. The flights canceled by 12:30 p.m. ET on Sunday included over 2,700 entering, departing from or within the United States, according to flight tracking website FlightAware.com. Over 1,500 flights were delayed, the data showed. American Airlines (AAL) had over 600 flight cancellations, the author notes. Almost 95% of the flights out of Charlotte Douglas International Airport in North Carolina, an American Airlines hub, were canceled, the FlightAware website showed. Other publicly traded companies in the space include Alaska Air (ALK), Delta Air Lines (DAL), JetBlue (JBLU), Southwest (LUV), Spirit Airlines (SAVE) and United Airlines (UAL).Reference Link

ShowHide Related Items >><<
UAL United Airlines
$46.74 /

-1.39 (-2.89%)

SAVE Spirit Airlines
$23.30 /

-0.48 (-2.02%)

LUV Southwest
$45.84 /

+0.045 (+0.10%)

JBLU JetBlue
$14.85 /

-0.28 (-1.85%)

DAL Delta Air Lines
$40.31 /

-1.15 (-2.77%)

ALK Alaska Air
$55.79 /

-0.715 (-1.27%)

AAL American Airlines
$18.50 /

-0.84 (-4.34%)

ALK Alaska Air
$55.79 /

-0.715 (-1.27%)

01/14/22 Barclays
Alaska Air price target lowered to $61 from $68 at Barclays
10/12/21 Susquehanna
Susquehanna sees constructive backdrop for air travel in 2022
10/01/21 JPMorgan
Alaska Air price target raised to $97 from $94 at JPMorgan
07/20/21 Raymond James
Alaska Air price target lowered to $78 from $85 at Raymond James
LUV Southwest
$45.84 /

+0.045 (+0.10%)

01/14/22 Barclays
Southwest price target lowered to $59 from $65 at Barclays
01/13/22 Susquehanna
Southwest downgraded to Neutral from Positive at Susquehanna
01/12/22 Wolfe Research
Southwest downgraded to Peer Perform from Outperform at Wolfe Research
01/12/22 Wolfe Research
Southwest downgraded to Peer Perform from Outperform at Wolfe Research
DAL Delta Air Lines
$40.31 /

-1.15 (-2.77%)

01/14/22 Raymond James
Delta Air Lines price target lowered to $53 from $55 at Raymond James
01/14/22 Barclays
Delta Air Lines price target lowered to $45 from $50 at Barclays
01/13/22 Goldman Sachs
Delta Air Lines price target raised to $40 from $39 at Goldman Sachs
01/13/22 Susquehanna
Delta Air Lines upgraded to Positive with $50 price target at Susquehanna
JBLU JetBlue
$14.85 /

-0.28 (-1.85%)

01/14/22 Barclays
JetBlue price target lowered to $17 from $20 at Barclays
01/03/22 MKM Partners
JetBlue downgraded to Sell from Neutral at MKM Partners
11/17/21
Fly Intel: Top five analyst upgrades
11/17/21 Exane BNP Paribas
JetBlue upgraded to Neutral from Underperform at Exane BNP Paribas
UAL United Airlines
$46.74 /

-1.39 (-2.89%)

01/14/22 Barclays
United Airlines price target lowered to $52 from $58 at Barclays
01/13/22 Susquehanna
United Airlines upgraded to Positive with $60 price target at Susquehanna
01/13/22 Susquehanna
United Airlines upgraded to Positive from Neutral at Susquehanna
01/07/22 BofA
BofA upgrades Delta to Buy, thinks poor sentiment could set up bounce
SAVE Spirit Airlines
$23.30 /

-0.48 (-2.02%)

01/14/22 Barclays
Spirit Airlines price target lowered to $38 from $46 at Barclays
01/13/22 Susquehanna
Spirit Airlines downgraded on cost pressures at Susquehanna
01/13/22 Susquehanna
Spirit Airlines downgraded to Neutral from Positive at Susquehanna
01/03/22 MKM Partners
Spirit Airlines downgraded to Neutral from Buy at MKM Partners
AAL American Airlines
$18.50 /

-0.84 (-4.34%)

01/11/22 Morgan Stanley
American Airlines upgraded to Equal Weight from Underweight at Morgan Stanley
01/03/22 Citi
Citi says omicron 'modest' risk to airlines, names Frontier preferred pick
12/06/21 Evercore ISI
American Airlines upgraded to In Line at Evercore ISI following 15% pullback
UAL United Airlines
$46.74 /

-1.39 (-2.89%)

SAVE Spirit Airlines
$23.30 /

-0.48 (-2.02%)

LUV Southwest
$45.84 /

+0.045 (+0.10%)

JBLU JetBlue
$14.85 /

-0.28 (-1.85%)

DAL Delta Air Lines
$40.31 /

-1.15 (-2.77%)

ALK Alaska Air
$55.79 /

-0.715 (-1.27%)

AAL American Airlines
$18.50 /

-0.84 (-4.34%)

UAL United Airlines
$46.74 /

-1.39 (-2.89%)

LUV Southwest
$45.84 /

+0.045 (+0.10%)

JBLU JetBlue
$14.85 /

-0.28 (-1.85%)

DAL Delta Air Lines
$40.31 /

-1.15 (-2.77%)

ALK Alaska Air
$55.79 /

-0.715 (-1.27%)

AAL American Airlines
$18.50 /

-0.84 (-4.34%)

UAL United Airlines
$46.74 /

-1.39 (-2.89%)

SAVE Spirit Airlines
$23.30 /

-0.48 (-2.02%)

LUV Southwest
$45.84 /

+0.045 (+0.10%)

JBLU JetBlue
$14.85 /

-0.28 (-1.85%)

DAL Delta Air Lines
$40.31 /

-1.15 (-2.77%)

ALK Alaska Air
$55.79 /

-0.715 (-1.27%)

AAL American Airlines
$18.50 /

-0.84 (-4.34%)

UAL United Airlines
$46.74 /

-1.39 (-2.89%)

SAVE Spirit Airlines
$23.30 /

-0.48 (-2.02%)

LUV Southwest
$45.84 /

+0.045 (+0.10%)

JBLU JetBlue
$14.85 /

-0.28 (-1.85%)

DAL Delta Air Lines
$40.31 /

-1.15 (-2.77%)

AAL American Airlines
$18.50 /

-0.84 (-4.34%)

Periodicals
Some Starbucks, Chipotle sites limiting operations over Omicron, WSJ reports » 15:42
01/16/22
01/16
15:42
01/16/22
15:42
SBUX

Starbucks

$100.13 /

-2.17 (-2.12%)

, CMG

Chipotle

$1,497.82 /

-7.88 (-0.52%)

Chains such as Starbucks…

Chains such as Starbucks (SBUX) and Chipotle (CMG) said they are temporarily limiting operations at individual stores or regions as they face labor shortages and a rise in COVID-19 cases, The Wall Street Journal's Heather Haddon reports. Other restaurant operators said more of their staff are testing positive for the coronavirus in the Omicron surge than during the growth of the earlier Delta variant and are voluntarily closing for stretches as a result, the publication notes. Reference Link

ShowHide Related Items >><<
SBUX Starbucks
$100.13 /

-2.17 (-2.12%)

CMG Chipotle
$1,497.82 /

-7.88 (-0.52%)

SBUX Starbucks
$100.13 /

-2.17 (-2.12%)

01/07/22 Oppenheimer
Oppenheimer downgrades Starbucks on lack of earnings upside potential
01/07/22 RBC Capital
RBC downgrades Starbucks on balanced risk/reward profile
01/07/22 RBC Capital
Starbucks downgraded to Sector Perform from Outperform at RBC Capital
01/07/22 Oppenheimer
Starbucks downgraded to Perform from Outperform at Oppenheimer
CMG Chipotle
$1,497.82 /

-7.88 (-0.52%)

01/14/22 Evercore ISI
Evercore ups Texas Roadhouse to Outperform on underappreciated recovery leverage
01/14/22 Morgan Stanley
Chipotle upgraded to Overweight from Equal Weight at Morgan Stanley
01/07/22 Oppenheimer
Chipotle upgraded to Outperform at Oppenheimer with stock down 17% from high
01/07/22 Oppenheimer
Chipotle upgraded to Outperform from Perform at Oppenheimer
SBUX Starbucks
$100.13 /

-2.17 (-2.12%)

CMG Chipotle
$1,497.82 /

-7.88 (-0.52%)

SBUX Starbucks
$100.13 /

-2.17 (-2.12%)

SBUX Starbucks
$100.13 /

-2.17 (-2.12%)

CMG Chipotle
$1,497.82 /

-7.88 (-0.52%)

SBUX Starbucks
$100.13 /

-2.17 (-2.12%)

CMG Chipotle
$1,497.82 /

-7.88 (-0.52%)

Periodicals
Target CEO sees less store trips as consumers confront inflation, Bloomberg says » 15:31
01/16/22
01/16
15:31
01/16/22
15:31
TGT

Target

$221.49 /

-4.35 (-1.93%)

Target's top…

Target's top executive said U.S. consumers will drive less and consolidate their shopping into fewer trips as they adjust to pricier gasoline and the highest inflation rate in almost four decades, Bloomberg's Brendan Case reports. Shoppers are also likely to eat more at home and seek cheaper generic-brand goods in an effort to ease the blow from rising prices, Chief Executive Officer Brian Cornell said Sunday at a National Retail Federation event in New York. Reference Link

ShowHide Related Items >><<
TGT Target
$221.49 /

-4.35 (-1.93%)

TGT Target
$221.49 /

-4.35 (-1.93%)

01/14/22 JPMorgan
Target removed from Analyst Focus List at JPMorgan
01/12/22 Truist
Truist starts Target at Buy, says company to still be primary share gainer
01/12/22 Truist
Target initiated with a Buy at Truist
01/07/22 Deutsche Bank
Target price target lowered to $312 from $318 at Deutsche Bank
TGT Target
$221.49 /

-4.35 (-1.93%)

TGT Target
$221.49 /

-4.35 (-1.93%)

TGT Target
$221.49 /

-4.35 (-1.93%)

TGT Target
$221.49 /

-4.35 (-1.93%)

Periodicals
Walmart filings reveal plans to create cryptocurrency, NFTs, Bloomberg says » 15:08
01/16/22
01/16
15:08
01/16/22
15:08
WMT

Walmart

$145.04 /

-0.51 (-0.35%)

Walmart is preparing to…

Walmart is preparing to create its own cryptocurrency and collection of non-fungible tokens, filings with the U.S. Patent and Trademark Office show, setting the stage for meeting its customers in the emerging metaverse, Bloomberg's Brendan Case and Susan Decker report. The retailer sought several new trademarks in December that show it intends to make and sell virtual goods such as electronics, decor, toys, sporting goods and personal-care products, the authors note. The applications were among a flurry the company filed on Dec. 30, including three under "Walmart Connect" - the name of the company's existing digital advertising venture -- for a financial exchange for virtual currency and advertising. Applications also were filed for "Verse to Store," "Verse to Curb" and "Verse to Home" for shopping services. It's also seeking trademarks to apply the Walmart name and "fireworks" logo to heath-care services and education in virtual and augmented reality, the publication adds. Reference Link

ShowHide Related Items >><<
WMT Walmart
$145.04 /

-0.51 (-0.35%)

WMT Walmart
$145.04 /

-0.51 (-0.35%)

01/12/22 Truist
Truist starts Walmart at Hold, cites potential adverse impact from inflation
01/12/22 Truist
Truist starts Dollar General at Hold, citing inflationary headwinds
01/12/22 Truist
Walmart initiated with a Hold at Truist
01/07/22 Jefferies
Jefferies upgraded Trade Desk to Buy, highlights five reasons to be positive
WMT Walmart
$145.04 /

-0.51 (-0.35%)

WMT Walmart
$145.04 /

-0.51 (-0.35%)

WMT Walmart
$145.04 /

-0.51 (-0.35%)

WMT Walmart
$145.04 /

-0.51 (-0.35%)

Upgrade
Sands China upgraded to Conviction Buy from Buy at Goldman Sachs » 09:42
01/16/22
01/16
09:42
01/16/22
09:42
SCHYY

Sands China

$27.25 /

+5.46 (+25.06%)

Goldman Sachs analyst…

Goldman Sachs analyst Simon Cheung added Sands China to his firm's Conviction List, while keeping a Buy rating on the name as he sees more upside in the near-term from closing its valuation discount versus peers. With the gaming license issues soon to be behind the company, the analyst expect investor focus to soon shift back to pace of GGR/EBITDA recovery, for which he continues to prefer those more exposed to grind mass/non-gaming segments, including Sands China, and more growth with new projects in the pipeline.

ShowHide Related Items >><<
SCHYY Sands China
$27.25 /

+5.46 (+25.06%)

SCHYY Sands China
$27.25 /

+5.46 (+25.06%)

11/26/21 Credit Suisse
Credit Suisse upgrades Macau stocks with 'light at the end of the tunnel'
11/24/21 Credit Suisse
Sands China upgraded to Outperform from Neutral at Credit Suisse
11/19/21 JPMorgan
Sands China upgraded to Neutral from Underweight at JPMorgan
09/15/21 JPMorgan
Sands China downgraded to Underweight from Overweight at JPMorgan
SCHYY Sands China
$27.25 /

+5.46 (+25.06%)

Upgrade
Las Vegas Sands upgraded to Conviction Buy from Buy at Goldman Sachs » 09:42
01/16/22
01/16
09:42
01/16/22
09:42
LVS

Las Vegas Sands

$42.99 /

+5.33 (+14.15%)

Goldman Sachs analyst…

Goldman Sachs analyst Simon Cheung added Las Vegas Sands to his firm's Americas Conviction List, keeping a Buy rating on the shares with a price target of $66, down from $67. The analyst now sees scope for re-rating following the details of the proposed Gaming Law revision, which creates a legal framework implying comparable upside versus his prior base case on unchanged fundamentals, with materially less regulatory downside risk.

ShowHide Related Items >><<
LVS Las Vegas Sands
$42.99 /

+5.33 (+14.15%)

LVS Las Vegas Sands
$42.99 /

+5.33 (+14.15%)

01/14/22 Stifel
Macau gaming stocks should finally get 'nice relief rally,' says Stifel
01/11/22 JPMorgan
JPMorgan upgrades Las Vegas Sands, adds to Analyst Focus List
01/11/22 JPMorgan
Las Vegas Sands upgraded to Overweight from Neutral at JPMorgan
01/10/22 Citi
Las Vegas Sands price target lowered to $57 from $58.50 at Citi
LVS Las Vegas Sands
$42.99 /

+5.33 (+14.15%)

LVS Las Vegas Sands
$42.99 /

+5.33 (+14.15%)

LVS Las Vegas Sands
$42.99 /

+5.33 (+14.15%)

LVS Las Vegas Sands
$42.99 /

+5.33 (+14.15%)

On The Fly
Week in SPAC News: Suneva Medical, Viveon Health Acquisition to merge » 09:31
01/16/22
01/16
09:31
01/16/22
09:31
VHAQ

Viveon Health Acquisition

$10.04 /

-0.01 (-0.10%)

, CHWA

CHW Acquisition

$9.76 /

+ (+0.00%)

, ACAB

Atlantic Coastal Acquisition II

/

+

, PPYA

Papaya Growth Opportunity I

/

+

, CSLM

Consilium Acquisition I

/

+

, WNNR

Andretti Acquisition

/

+

, GHIX

Gores Holdings IX

/

+

, WAVS

Western Acquisition Ventures

/

+

, VCXB

10X Capital Venture Acquisition III

/

+

, ITAQ

Industrial Tech Acquisitions II

/

+

, BRAC

Broad Capital Acquisition

/

+

In SPAC news this week,…

ShowHide Related Items >><<
VHAQ Viveon Health Acquisition
$10.04 /

-0.01 (-0.10%)

CHWA CHW Acquisition
$9.76 /

+ (+0.00%)

CHWA CHW Acquisition
$9.76 /

+ (+0.00%)

Conference/Events
Morgan Stanley consumer/retail analysts hold analyst/industry conference call » 22:15
01/15/22
01/15
22:15
01/15/22
22:15

Restaurants & Food…

Restaurants & Food Distribution Analyst Glass, Dept Store Analyst Greenberger and US Hardlines, Broadlines Analyst Gutman discuss the outlook for the Consumer Industry for 2022 on an Analyst/Industry conference call to be held on January 20 at 11 am.

Conference/Events
Atai Life Sciences to host KOL conference call » 22:15
01/15/22
01/15
22:15
01/15/22
22:15
ATAI

Atai Life Sciences

$5.95 /

-0.26 (-4.19%)

Management holds a Key…

Management holds a Key Opinion Leader conference with Dr. Keefe of Duke University and CEO & Co-Founder Pando of Recognify Life Sciences to discuss the recently completed Phase 2a trial for RL-007 and the preliminary topline data on January 18 at 12 pm. Webcast Link

ShowHide Related Items >><<
ATAI Atai Life Sciences
$5.95 /

-0.26 (-4.19%)

ATAI Atai Life Sciences
$5.95 /

-0.26 (-4.19%)

11/30/21
Fly Intel: Top five analyst initiations
11/30/21 Maxim
Atai Life Sciences initiated with a Buy at Maxim
11/30/21 Maxim
Atai Life Sciences initiated with a Buy at Maxim
11/22/21 Canaccord
Atai Life Sciences weakness a buying opportunity, says Canaccord
ATAI Atai Life Sciences
$5.95 /

-0.26 (-4.19%)

  • 18
    Jun
ATAI Atai Life Sciences
$5.95 /

-0.26 (-4.19%)

ATAI Atai Life Sciences
$5.95 /

-0.26 (-4.19%)

Conference/Events
23andMe to host virtual research and development day » 22:07
01/15/22
01/15
22:07
01/15/22
22:07
ME

23andMe

$5.17 /

-0.25 (-4.62%)

Virtual Research and…

Virtual Research and Development Day to be held on January 18 at 11 am. Webcast Link

ShowHide Related Items >><<
ME 23andMe
$5.17 /

-0.25 (-4.62%)

ME 23andMe
$5.17 /

-0.25 (-4.62%)

11/14/21 Citi
23andMe downgraded to Neutral from Buy at Citi
08/16/21 Credit Suisse
23andMe initiated with an Outperform at Credit Suisse
08/16/21 Citi
23andMe price target lowered to $12 from $14 at Citi
07/13/21 Citi
23andMe initiated with a Buy at Citi
ME 23andMe
$5.17 /

-0.25 (-4.62%)

ME 23andMe
$5.17 /

-0.25 (-4.62%)

ME 23andMe
$5.17 /

-0.25 (-4.62%)

ME 23andMe
$5.17 /

-0.25 (-4.62%)

Conference/Events
Atai Life Sciences to host KOL conference call » 22:04
01/15/22
01/15
22:04
01/15/22
22:04
ATAI

Atai Life Sciences

$5.95 /

-0.26 (-4.19%)

Management holds a Key…

Management holds a Key Opinion Leader conference with Dr. Keefe of Duke University and CEO & Co-Founder Pando of Recognify Life Sciences to discuss the recently completed Phase 2a trial for RL-007 and the preliminary topline data on January 18 at 12 pm. Webcast Link

ShowHide Related Items >><<
ATAI Atai Life Sciences
$5.95 /

-0.26 (-4.19%)

ATAI Atai Life Sciences
$5.95 /

-0.26 (-4.19%)

11/30/21
Fly Intel: Top five analyst initiations
11/30/21 Maxim
Atai Life Sciences initiated with a Buy at Maxim
11/30/21 Maxim
Atai Life Sciences initiated with a Buy at Maxim
11/22/21 Canaccord
Atai Life Sciences weakness a buying opportunity, says Canaccord
ATAI Atai Life Sciences
$5.95 /

-0.26 (-4.19%)

  • 18
    Jun
ATAI Atai Life Sciences
$5.95 /

-0.26 (-4.19%)

ATAI Atai Life Sciences
$5.95 /

-0.26 (-4.19%)

Hot Stocks
GSK says rejected 3 Unilever bids that 'undervalued' Consumer Healthcare unit » 16:37
01/15/22
01/15
16:37
01/15/22
16:37
GSK

GlaxoSmithKline

$45.48 /

+0.44 (+0.98%)

, PFE

Pfizer

$54.94 /

-0.59 (-1.06%)

, UN

Unilever

$60.50 /

+ (+0.00%)

, UL

Unilever

$54.30 /

+0.645 (+1.20%)

A press release was…

A press release was issued today by GlaxoSmithKline (GSK) to the London Stock Exchange, entitled "Update - GSK Consumer Healthcare," that states in part: "GlaxoSmithKline (GSK) plc today confirms that it has received three unsolicited, conditional and non-binding proposals from Unilever plc to acquire the GSK Consumer Healthcare business. The latest proposal received on 20th December 2021 was for a total acquisition value of GBP 50 billion comprising GBP 41.7 billion in cash and GBP 8.3 billion in Unilever shares. The Consumer Healthcare business is a Joint Venture between GSK and Pfizer, with GSK holding a majority controlling interest of 68% and Pfizer 32%. GSK rejected all three proposals made on the basis that they fundamentally undervalued the Consumer Healthcare business and its future prospects. The Board of GSK is strongly focused on maximising value for GSK shareholders and has carefully evaluated each Unilever proposal. In doing so, the Board and its advisers assessed the proposals relative to the financial planning assessments completed to support the proposed demerger of the business in mid-2022, including the sales growth outlook set out below... The business has an exceptional portfolio of world-class, category-leading brands; global scale with footprint and distribution capability to serve more than 100 markets; strong brand building, innovation and digital capabilities; and offers a unique proposition that combines trusted science with human understanding... The business is well-positioned to sustainably grow ahead of its categories in the years to come. The fundamentals for the GBP 150 billion consumer healthcare sector are strong, reflecting an increased focus on health and wellness, significant demand from an ageing population and emerging middle class, and sizeable unmet consumer needs. Over the period 2019-2021 the Consumer Healthcare business delivered a 4% organic sales growth CAGR2 outpacing its categories and despite the adverse impact of the COVID pandemic. Superior sales growth for the business is expected to result from a strategy that puts the consumer at the heart of the business to better address every-day health and wellness needs, in particular by increasing household penetration of its leading brands and capitalising on new and emerging growth opportunities arising from innovation and the use of new technologies and digital platforms, all underpinned by continued strong execution and financial discipline. Over the medium term, superior sales growth is expected to be primarily driven by continued momentum of key brands in Oral Care, VMS, and Pain Relief; accelerating innovation in the US and China; and further growth in emerging markets. Reflecting these trends, and the investments made and planned for the business, the Board of GSK is confident that the Consumer Healthcare business can sustainably deliver annual organic sales growth in the range of 4-6% CER over the medium term. The combination of superior organic sales growth, operating margin expansion and consistent high cash generation will, we believe, offer both existing and prospective shareholders a highly attractive financial profile that facilitates continued investment in growth, the delivery of attractive returns and the opportunity of continued participation in long-term value creation. The Board of GSK unanimously concluded that the proposals were not in the best interests of GSK shareholders as they fundamentally undervalued the Consumer Healthcare business and its future prospects. The Board of GSK therefore remains focused on executing its proposed demerger of the Consumer Healthcare business, to create a new independent global category-leading consumer company which, subject to approval from shareholders, is on track to be achieved in mid-2022. GSK intends to share further details of the strategy, brands, capabilities and operations, including detailed financial information and future growth ambitions for the new Consumer Healthcare business at a virtual Capital Markets Day for investors and analysts on Monday 28th February 2022."

ShowHide Related Items >><<
UN Unilever
$60.50 /

+ (+0.00%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

01/04/22 JPMorgan
GlaxoSmithKline price target raised to 1,710 GBp from 1,580 GBp at JPMorgan
01/04/22 JPMorgan
JPMorgan places 'positive Catalyst watch' on GSK, ups target
12/21/21 H.C. Wainwright
Vir Biotechnology price target raised to $300 from $200 at H.C. Wainwright
12/16/21 Stifel
Adagio story 'even more complicated' after preprints on ADG20, says Stifel
PFE Pfizer
$54.94 /

-0.59 (-1.06%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
UN Unilever
$60.50 /

+ (+0.00%)

01/10/22 Citi
Unilever resumed with a Buy at Citi
11/01/21 Bernstein
Unilever upgraded to Market Perform from Underperform at Bernstein
09/16/21 Deutsche Bank
Unilever downgraded to Hold from Buy at Deutsche Bank
09/02/21 JPMorgan
Unilever downgraded to Underweight from Neutral at JPMorgan
UL Unilever
$54.30 /

+0.645 (+1.20%)

09/02/21
Fly Intel: Top five analyst downgrades
PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

Periodicals
DirecTV to drop One America News in blow to conservative channel, Bloomberg says » 12:38
01/15/22
01/15
12:38
01/15/22
12:38
T

AT&T

$27.18 /

+0.37 (+1.38%)

, TPG

TPG

$32.74 /

-1.24 (-3.65%)

DirecTV, which is owned…

DirecTV, which is owned by AT&T (T) and TPG (TPG) via a joint venture, plans to drop One America News Network, dealing a major blow to the conservative channel that's been criticized for spreading misinformation and had a loyal fan in former President Donald Trump, Bloomberg's Gerry Smith reports. The satellite-TV provider has notified OAN's owner, Herring Networks, that it plans to stop carrying the company's two channels when their contract expires. Herring Networks also owns AWE, a lifestyle channel that stands for "A Wealth of Entertainment." Reference Link

ShowHide Related Items >><<
T AT&T
$27.18 /

+0.37 (+1.38%)

T AT&T
$27.18 /

+0.37 (+1.38%)

01/11/22 Citi
Citi adds Crown Castle, Switch to 'Positive Catalyst Watch List'
01/11/22 Citi
Citi adds AT&T to 'positive catalyst watch list,' keeps $29 target
01/07/22 Wells Fargo
Wells upgrades AT&T to neutral with downside risks 'more limited'
01/07/22 Wells Fargo
AT&T upgraded to Equal Weight from Underweight at Wells Fargo
TPG TPG
$32.74 /

-1.24 (-3.65%)

T AT&T
$27.18 /

+0.37 (+1.38%)

  • 13
    Jan
TPG TPG
$32.74 /

-1.24 (-3.65%)

T AT&T
$27.18 /

+0.37 (+1.38%)

TPG TPG
$32.74 /

-1.24 (-3.65%)

T AT&T
$27.18 /

+0.37 (+1.38%)

T AT&T
$27.18 /

+0.37 (+1.38%)

Periodicals
Barron's sees buying opportunity in Shell buybacks, low-carbon energy shift » 09:48
01/15/22
01/15
09:48
01/15/22
09:48
RDS.A

Royal Dutch Shell

$50.06 /

+0.83 (+1.69%)

, RDS.B

Royal Dutch Shell

$50.09 /

+0.84 (+1.71%)

, COP

ConocoPhillips

$86.80 /

+3.23 (+3.87%)

Activist shareholder…

Activist shareholder Third Point argues that Royal Dutch Shell is worth more if the oil company were broken up, but if the business remains whole, two key factors could enhance its value-the promise to return 20% to 30% of its cash flow from operations to shareholders in dividends and buybacks to 2025, and its shift to low-carbon energy, Rupert Steiner writes in this week's edition of Barron's. This is in addition to Shell 's (RDS.A) plans for $7B of the $9.5B in proceeds from the sale of its Permian basin oil field to ConocoPhillips (COP) to be returned to shareholders, the author notes. Shell's transition to investing in low-carbon solutions is also key to its future growth, the publication adds. Shell's shares, along with many of its peers, have been more than halved since the beginning of the pandemic in January 2020. Now could be a buying opportunity, Steiner contends. Reference Link

ShowHide Related Items >><<
RDS.B Royal Dutch Shell
$50.09 /

+0.84 (+1.71%)

RDS.A Royal Dutch Shell
$50.06 /

+0.83 (+1.69%)

COP ConocoPhillips
$86.80 /

+3.23 (+3.87%)

RDS.A Royal Dutch Shell
$50.06 /

+0.83 (+1.69%)

01/07/22 Exane BNP Paribas
Royal Dutch Shell downgraded to Neutral from Outperform at Exane BNP Paribas
12/03/21 Deutsche Bank
Royal Dutch Shell price target raised to 2,038 GBp at Deutsche Bank
11/17/21 Scotiabank
Royal Dutch Shell upgraded to Outperform at Scotiabank
11/17/21 Scotiabank
Shell Class B upgraded to Outperform from Sector Perform at Scotiabank
RDS.B Royal Dutch Shell
$50.09 /

+0.84 (+1.71%)

11/15/21 UBS
Royal Dutch Shell price target raised to 2,125 GBp from 1,860 GBp at UBS
COP ConocoPhillips
$86.80 /

+3.23 (+3.87%)

01/14/22 Truist
ConocoPhillips price target raised to $111 from $100 at Truist
01/13/22 Scotiabank
ConocoPhillips downgraded to Sector Perform from Outperform at Scotiabank
01/03/22 Mizuho
ConocoPhillips price target lowered to $98 from $101 at Mizuho
11/30/21 Mizuho
ConocoPhillips price target raised to $101 from $99 at Mizuho
RDS.A Royal Dutch Shell
$50.06 /

+0.83 (+1.69%)

COP ConocoPhillips
$86.80 /

+3.23 (+3.87%)

RDS.B Royal Dutch Shell
$50.09 /

+0.84 (+1.71%)

RDS.A Royal Dutch Shell
$50.06 /

+0.83 (+1.69%)

COP ConocoPhillips
$86.80 /

+3.23 (+3.87%)

RDS.B Royal Dutch Shell
$50.09 /

+0.84 (+1.71%)

RDS.A Royal Dutch Shell
$50.06 /

+0.83 (+1.69%)

COP ConocoPhillips
$86.80 /

+3.23 (+3.87%)

COP ConocoPhillips
$86.80 /

+3.23 (+3.87%)

Periodicals
Take-Two playing the long game, stock looks cheap, Barron's says » 09:43
01/15/22
01/15
09:43
01/15/22
09:43
TTWO

Take-Two

$152.57 /

-2.2 (-1.42%)

, ZNGA

Zynga

$8.95 /

-0.1 (-1.10%)

This past week, Take-Two…

This past week, Take-Two (TTWO) made a significant effort to right its ship. The company agreed to buy mobile-game maker Zynga (ZNGA) for $12.7 billion, Connor Smith writes in this week's edition of Barron's. Zynga gives Take-Two a larger roster of game developers along with a treasure trove of data and mobile-advertising resources, the author notes. Most of all, it brings scale, says Take-Two CEO Strauss Zelnick. The stock currently trades at about 23 times earnings estimates for the coming year, below a three-year average of 28 times. At that average multiple, Take-Two shares would be more than 20% higher, at $187. And with Zynga, Take-Two has taken control of its destiny, Smith contends.Reference Link

ShowHide Related Items >><<
ZNGA Zynga
$8.95 /

-0.1 (-1.10%)

TTWO Take-Two
$152.57 /

-2.2 (-1.42%)

TTWO Take-Two
$152.57 /

-2.2 (-1.42%)

01/13/22 Stifel
Zynga downgraded to Hold from Buy at Stifel
01/12/22 BMO Capital
Take-Two upgraded to Outperform from Market Perform at BMO Capital
01/11/22 Truist
Zynga downgraded to Hold from Buy at Truist
01/11/22 KeyBanc
Zynga downgraded to Sector Weight from Overweight at KeyBanc
ZNGA Zynga
$8.95 /

-0.1 (-1.10%)

ZNGA Zynga
$8.95 /

-0.1 (-1.10%)

TTWO Take-Two
$152.57 /

-2.2 (-1.42%)

ZNGA Zynga
$8.95 /

-0.1 (-1.10%)

TTWO Take-Two
$152.57 /

-2.2 (-1.42%)

TTWO Take-Two
$152.57 /

-2.2 (-1.42%)

ZNGA Zynga
$8.95 /

-0.1 (-1.10%)

TTWO Take-Two
$152.57 /

-2.2 (-1.42%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.